Structural Basis, Manufacturing Technologies, and Applications of Recombinant Human Albumin and Recombinant Human Transferrin
Structural Basis, Manufacturing Technologies, and Applications of Recombinant Human Albumin and Recombinant Human Transferrin
Albumin and transferrin are two essential functional proteins in human plasma. Albumin plays central roles in maintaining plasma colloid osmotic pressure and transporting a broad spectrum of low-molecular-weight ligands, whereas transferrin is a key regulator of iron metabolism and is also implicated in immune responses and inflammation-associated iron redistribution. Conventional plasma-derived products have inherent limitations in supply stability, pathogen safety, and lot-to-lot consistency. Recombinant human albumin and recombinant human transferrin can be produced via genetic engineering and fermentation, achieving high similarity to native human proteins in amino-acid sequence and higher-order structure while offering scalable manufacturing and improved controllability of safety risks. They have been widely adopted for cell culture media optimization and for drug delivery/formulation development. In clinical supportive therapy, their use remains largely driven by product-specific evidence generation, staged clinical development, and region-specific regulatory access. Systematic research on their structures and physiological functions, recombinant production routes, and application scenarios provides a more standardized human-protein material foundation for cell culture and formulation development.
I. Biological Background of Plasma Carrier Proteins
1.1 Overview of Human Plasma Protein Composition
(1) Human plasma proteins are dominated by albumin and globulins, with albumin accounting for approximately 50%–60% of total plasma protein and serving as the primary contributor to plasma colloid osmotic pressure.
(2) In addition to albumin, transferrin, lipoproteins, complement components, and coagulation factors collectively form a complex humoral transport and defense network responsible for nutrient transport, metal-ion homeostasis, coagulation, and immune modulation.
1.2 Core Physiological Functions of Albumin and Transferrin
(1) Albumin
Albumin is a highly soluble, stable single-chain protein with multiple hydrophobic binding cavities and negatively charged surface regions that enable noncovalent association with diverse small-molecule ligands. Representative functions include:
① Maintaining plasma colloid osmotic pressure, preventing excessive fluid extravasation into interstitial spaces, and supporting circulating volume and tissue fluid balance;
② Acting as a nonspecific carrier for fatty acids, bilirubin, hormones, selected drugs, and metabolic small molecules, thereby affecting distribution, half-life, and pharmacokinetic/pharmacodynamic behavior;
③ Contributing to radical scavenging and antioxidant buffering through structural elements such as free thiols and aromatic residues, mitigating damage associated with inflammation and oxidative stress.
(2) Transferrin
Transferrin is the principal iron-binding and iron-transport protein in plasma. Key functions include:
① Binding Fe³⁺ in plasma with adjustable saturation and delivering iron safely and controllably to tissues such as bone marrow and liver, thereby limiting oxidative injury driven by labile iron;
② Regulating cellular iron uptake via transferrin receptor–mediated endocytosis (TfR1/TfR2) and maintaining intracellular iron homeostasis required for DNA synthesis, mitochondrial function, and activities of iron-containing enzymes;
③ Participating in “nutritional immunity” during inflammation and infection by modulating transferrin levels and saturation to restrict pathogen-accessible iron and indirectly suppress microbial growth.
1.3 Limitations of Plasma-Derived Products and the Recombinant Strategy
(1) Plasma-derived protein products depend on blood donation systems; supply stability and cost control are constrained by donor populations, screening strategies, and regional variability.
(2) Although modern pathogen screening and viral inactivation technologies have substantially reduced risk, plasma-derived products retain theoretical residual risks related to known/unknown pathogens and prion transmission, and can exhibit batch-to-batch differences in impurity profiles and microheterogeneity.
(3) Recombinant production via genetic engineering enables reconstruction of plasma proteins with native-like structural and functional properties under more controllable safety and scalable manufacturing conditions, providing standardized alternatives for multiple application contexts.
II. Recombinant Human Albumin (rHA/rHSA): Structure, Manufacturing, and Function
2.1 Structural and Physicochemical Properties
(1) Recombinant human albumin is typically highly homologous to native human serum albumin in amino-acid sequence, preserving key functional structural elements responsible for ligand binding, antioxidant activity, and surface charge distribution, thereby approximating endogenous protein performance in three-dimensional structure and function.
(2) Albumin exhibits high thermal stability and excellent solubility, maintaining conformational stability across a relatively broad pH and ionic-strength range, which supports diverse process and formulation conditions. In recombinant manufacturing, stringent purity control and de-aggregation strategies can further reduce aggregates and degradation products that may contribute to immunogenicity risk.
2.2 Overview of Recombinant Manufacturing Routes
(1) Expression systems
Recombinant human albumin can be expressed in yeast, plant cells, or other engineered hosts. Yeast systems often provide a balanced combination of expression level, fermentation scalability, and cost efficiency and are commonly used for industrial production; plant cell and whole-plant expression platforms can offer advantages in biosafety and flexible scaling.
(2) Fermentation and harvest
High-density cultivation and high-level expression are achieved in bioreactors with controlled dissolved oxygen, pH, carbon-source feeding, and induction parameters. Online monitoring supports process stability and batch-to-batch reproducibility. Cell removal and clarification are typically performed by centrifugation and filtration.
(3) Purification and quality control
Multi-step chromatography (e.g., affinity, ion exchange, and size exclusion) combined with ultrafiltration/concentration is used to remove host-cell proteins, residual nucleic acids, and low-molecular-weight impurities. Endotoxin, aggregate content, residual host DNA, and host-cell protein levels are tightly controlled to meet safety requirements for clinical-grade or high-stringency in vitro applications.
2.3 Principal Functions and Mechanistic Basis of Recombinant Human Albumin
(1) Maintenance of colloid osmotic pressure and intravascular volume support
Recombinant human albumin is expected to provide colloid osmotic pressure contributions comparable to native albumin. Clinical use for hypoalbuminemia or volume support is contingent upon product-specific indications and regional regulatory approvals, and should be evaluated within approved labeling or clinical research frameworks, including impacts on hemodynamic stability and tissue edema.
(2) Multi-ligand carrier function and drug transport
Albumin contains multiple hydrophobic pockets and charged surface regions that enable noncovalent complexation with fatty acids, bilirubin, and drug molecules. Recombinant albumin can be used in co-formulation or covalent conjugation strategies to extend the half-life of selected small molecules or biologics and improve pharmacokinetic profiles, supporting development of long-acting or enhanced-targeting formulations.
(3) Antioxidant buffering and cellular protection
Albumin’s free thiol and aromatic residues can react with oxidants, buffering reactive oxygen species and free radicals. Recombinant human albumin is expected to retain this antioxidant buffering capacity, potentially supporting mitigation of oxidative-stress–associated pathological states.
2.4 Representative Application Scenarios
(1) Clinical support and replacement therapy
In hypoalbuminemia, burns, severe infection, or surgery-associated volume deficits, recombinant human albumin may be used for colloid osmotic pressure and volume support in certain regions/products within approved indications or clinical research settings; efficacy and risk should follow guidelines, product labeling, and individualized assessment.
(2) Cell culture and biomanufacturing
In animal-component–free or reduced-animal-origin culture systems, recombinant human albumin can replace animal-derived albumin or serum components to stabilize culture conditions, improve viability of adherent/suspension cultures, and enhance productivity—particularly in high-safety-requirement production such as vaccines and antibodies.
(3) Drug and biologic formulation development
Albumin conjugation or albumin-binding–mediated half-life extension can increase systemic exposure and dosing convenience for small molecules, peptides, and protein therapeutics. Recombinant human albumin provides a more controllable and traceable carrier basis for constructing standardized drug–carrier systems.
III. Recombinant Human Transferrin (rTf): Structural Features and Applications
3.1 Structural Organization and Iron-Binding Characteristics
(1) Transferrin comprises two homologous lobes, each containing a high-affinity iron-binding site, and typically exists in mono-ferric or di-ferric forms. Iron binding induces conformational changes that modulate receptor affinity and cellular uptake efficiency, providing a structural basis for fine control of iron transport.
(2) In plasma, transferrin saturation is generally maintained at an intermediate level to ensure efficient iron transport while limiting labile iron that could drive Fenton chemistry and oxidative injury. Iron–transferrin complexes enter cells via receptor-mediated endocytosis; after iron release, apo-transferrin is recycled.
3.2 Key Points in Recombinant Production and Quality Control
(1) Expression and folding
Recombinant human transferrin is commonly produced in eukaryotic expression systems to support correct folding and relevant post-translational modifications (e.g., glycosylation) needed for receptor interaction and iron-binding function. Expression platforms must balance cost with consistency of protein quality.
(2) Iron-binding function and structural characterization
Functional integrity of iron-binding sites is verified using iron-binding assays, spectroscopy, and isothermal titration calorimetry (ITC), complemented by mass spectrometry, HPLC, and SDS-PAGE for purity and impurity profiling. For transferrin intended for cell culture or potential clinical use, endotoxin, residual host DNA, and host-cell protein must be strictly controlled.
3.3 Biological Functions of Recombinant Human Transferrin
(1) Iron transport and maintenance of cellular iron homeostasis
Given its close similarity to native transferrin in sequence and conformation, recombinant transferrin can support receptor-mediated cellular iron uptake, sustaining mitochondrial respiration, heme synthesis, and iron-dependent enzyme activities. This function is foundational for cell proliferation and metabolic integrity.
(2) Association with antioxidant protection and immune modulation
By tightly binding Fe³⁺ and reducing labile iron, transferrin indirectly suppresses iron-catalyzed radical formation and can mitigate oxidative-stress–related cellular injury. During infection and inflammation, transferrin levels and saturation contribute to iron restriction as part of host defense, representing a relevant node within immune-regulatory networks.
3.4 Application Directions
(1) Support in iron metabolism–related conditions
Disease-support use of recombinant human transferrin in iron metabolism disorders remains largely at research and translational stages. Feasibility as an iron distribution/modulation strategy depends on clear indication definitions, clinical evidence, and regulatory approvals, including benefit–risk evaluation in combination with iron supplementation or chelation regimens.
(2) Cell culture and serum-free media
In serum-free or low-serum media, recombinant human transferrin serves as a standardized iron carrier to replace serum or animal-derived transferrin, enabling precise iron supply control while reducing batch variability and contamination risk. It is broadly applicable to vaccine cell lines, antibody-producing cells, stem cells, and primary cell culture systems.
(3) Drug delivery and nano-carrier targeting
Because transferrin receptors are overexpressed in certain tumors and specific tissues, recombinant transferrin can be used as a targeting ligand or functional module for nano-carrier surface functionalization or drug conjugation, leveraging the Tf–TfR pathway to promote preferential cellular entry and reduce off-target exposure.
IV. Advantages and Development Outlook for Recombinant Human Plasma Proteins
4.1 Key Advantages Relative to Plasma-Derived Products
(1) Upstream biosafety: production is independent of human/animal plasma, mitigating blood-borne pathogen and prion risks at the source and supporting higher safety requirements.
(2) Quality consistency: stable engineered cell banks and standardized fermentation–purification workflows enable high lot-to-lot consistency in structure and impurity profiles, supporting formulation development and long-term risk control.
(3) Supply scalability: fermentation scale-up and process optimization can increase capacity, reducing dependence on donor resources and easing supply–demand constraints.
4.2 Remaining Technical and Regulatory Challenges
(1) Further reduction of aggregates, oxidative modifications, and trace impurities under scaled production conditions—while ensuring long-term immunological safety—remains a core optimization priority.
(2) Post-translational modification differences across expression systems (e.g., yeast, plants, mammalian cells) may affect in vivo behavior and require systematic pharmacokinetic, safety, and immunogenicity evaluation.
(3) For clinical use and high-stringency cell culture, robust evidence of equivalence or superiority versus plasma-derived products is required, together with strict regulatory expectations for quality standards, process consistency, and clinical data packages.
4.3 Future Directions
(1) At the structural level, protein engineering and site-specific modification may further optimize stability, half-life, and selected ligand-binding properties while maintaining human-like features, enabling function-enhanced albumin or transferrin derivatives.
(2) At the application level, combining recombinant albumin/transferrin with other recombinant ECM components, signaling proteins, and polysaccharide materials may help build cell culture and tissue engineering platforms that more closely recapitulate in vivo microenvironments, supporting regenerative medicine and advanced drug screening.
(3) From a regulatory and standardization perspective, as more recombinant plasma protein products enter industrial use, quality standards, characterization methods, and functional evaluation frameworks are expected to become more detailed and harmonized, clarifying technical boundaries and compliant development pathways.
V. Aladdin-Related Products
Catalog No. | Product Name | Grade and Purity |
Recombinant Human Serum Albumin from Oryza sativa,OsrHSA | for cell culture；≥99% | |
Recombinant Human Serum Albumin from Oryza sativa,OsrHSA | ≥96%；lyophilized powder | |
Recombinant Human Serum Albumin from Oryza sativa,OsrHSA | for cell culture；≥99% | |
Recombinant Human Apo-Transferrin Protein | Animal Free; Carrier Free；GMP；Bioactive；ActiBioPure™；High Performance；for cell culture；≥95%（SDS-PAGE） | |
Albumin human | ≥96% | |
Albumin human | Recombinant；≥90%（SDS-PAGE）；expressed in Pichia pastoris；5% in aqueous buffer | |
Albumin human | Recombinant；≥99%（agarose gel electrophoresis）；expressed in Saccharomyces cerevisiae；aqueous solution；10% in aqueous buffer | |
Albumin solution human | 30% in 0.85% sodium chloride；protease free |
Recombinant human albumin and recombinant human transferrin, by combining native-like structural/function fidelity with improved safety controllability and scalable manufacturing, provide key material support for clinical supportive care, cell culture, and drug delivery platforms, while also offering an important direction for upgrading or replacing conventional plasma-derived products and enabling next-generation biomaterial systems.
Aladdin: https://www.aladdinsci.com/